{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-037887","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.833489+00:00","generated_at":"2026-06-12T10:31:51.929476+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ionis and Novartis expand Lp(a) collaboration; Ionis gets $60M upfront for next-gen therapy","bullets":["Ionis receives $60 million upfront from Novartis for next-generation Lp(a) compound.","Builds on existing pelacarsen collaboration; Novartis to handle development and commercialization.","Agreement subject to HSR antitrust clearance.","Ionis eligible for additional milestone payments and tiered royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-037887","json":"https://secwatch.observer/filing/0001140361-23-037887.json","markdown":"https://secwatch.observer/filing/0001140361-23-037887.md","text":"https://secwatch.observer/filing/0001140361-23-037887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036123037887/0001140361-23-037887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036123037887/brhc20056974_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:31:51.929476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9ffb79a805a21ee5bc1e94aedcd0a25151c43c5","claim":"IONIS PHARMACEUTICALS INC entered into Agreement with Novartis Pharma AG (effective 2023-08-03).","evidence_excerpt":"On August 3, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that the Company entered into a collaboration and license agreement (the “ Agreement ”) with Novartis Pharma AG (“ Novartis ”) to discover, develop and commercialize a novel medicine for patients with lipoprotein(a)-driven cardiovascular disease.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036123037887/0001140361-23-037887-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Novartis Pharma AG"},{"label":"Effective","value":"2023-08-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}